Docking 14 million virtual isoquinuclidines against the mu and kappa opioid receptors reveals dual antagonists-inverse agonists with reduced withdrawal effects. - Vigneron SF; Ohno S; Braz J; Kim JY; Kweon OS; Webb C; Billesbølle C; Bhardwaj K; Irwin J; Manglik A; Basbaum AI; Ellman JA; et al. (BioRxiv : the preprint server for biology, 2025)